| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02322099 Details | 2022-05-26 Interventional | 4 | 53 | Alendronate Calcium Calcium Carbona… Cholecalciferol Tenofovir Vitamin D Bone Deminerali… Bone Deminerali… | Due to the COVID-19 pandemic the study was terminated prematurely - | |||
| NCT02003742 Details | 2022-05-26 Interventional | 3 | 104 | Tamsulosin Lower Urinary T… | The study was stopped because in two other clinical studies the drug was not superior in
comparison with placebo - | |||
| NCT01369199 NCT01534611 Details | 2022-05-26 Interventional | 3 | 28 | Entecavir Peginterferon a… Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | - Early termination of recruitment per Data and Safety Monitoring Board. 1 case with multiple central and local lab discrepancies was not considered to have HBeAg loss since central lab was always negative. | |||
| NCT04676243 Details | 2022-05-25 Interventional | 3 | 0 | Quizartinib Acute Myeloid L… | Study turned out no longer feasible - | |||
| NCT04400799 Details | 2022-05-25 Interventional | 3 | 475 | Enoxaparin COVID-19 Embolism Pulmonary Embol… Thrombosis Venous Thrombos… Pulmonary Embol… | due to results from interim analysis - | |||
| NCT03845322 Details | 2022-05-25 Interventional | 1 | [1 Refs] | 0 | Curcumin Hematoma Hematoma, Subdu… Hematoma, Subdu… Recurrence | 12 Screen failures and Changes in PI and loss of residency program. - | ||
| NCT02616055 Details | 2022-05-25 Interventional | 2 | 15 | XL647 Kidney Diseases Polycystic Kidn… Polycystic Kidn… Autosomal Domin… | Sponsor opened Phase 2 Study. - | |||
| NCT03378466 Details | 2022-05-24 Interventional | 2 | 178 | Calcium heparin Heparin Shock Shock, Septic Septic Shock Vasodilatory Sh… | infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants
coming to an end. - | |||
| NCT02999854 2016-004672-21 Details | 2022-05-24 Interventional | 3 | 63 | Cyclophosphamid… Leukemia Myelodysplastic… Precursor Cell … Acute Lymphobla… Acute Myeloid L… Myelodysplastic… | Insufficient efficacy, terminated by Sponsor - | |||
| NCT02906020 2016-000657-12 Details | 2022-05-24 Interventional | 2 | 273 | Venglustat Parkinson Disea… Parkinson's Dis… | The topline results of the 52-week double-blind placebo-controlled period were analyzed. The
study did not meet the primary or secondary endpoints. Based on these results, the decision was
made to halt the long-term follow-up period of the study This study did not achieve its primary or secondary endpoints at the time of the analysis of the double-blind 52-week treatment period of Part 2 and was terminated early. | |||
| NCT02783404 Details | 2022-05-24 Interventional | 4 | [4 Refs] | 40 | Amoxicillin Clavulanic Acid Clavulanic Acid… Bacteremia Endocarditis Bacteraemia | Significant results (no control neither amoxicillin new arms needed) - | ||
| NCT02113176 Details | 2022-05-24 Interventional | 1/2 | 0 | Minocycline Aneurysm Hemorrhage Subarachnoid An… | Funding of minocycline - | |||
| NCT03444753 Details | 2022-05-23 Interventional | 1 | 82 | Ipilimumab Nivolumab Advanced Cancer | business objectives have changed - | |||
| NCT02449161 Details | 2022-05-23 Interventional | 3 | 60 | Medroxyprogeste… Amenorrhea Menorrhagia | Missing fund to continue - | |||
| NCT05292976 Details | 2022-05-20 Interventional | 3 | 0 | Albuterol Methacholine Ch… Asthma Bronchial Asthm… | Business reasons - | |||
| NCT04264806 2019-003576-40 Details | 2022-05-20 Interventional | 2 | 0 | Azacitidine Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome | The cusatuzumab MDS strategy is under revision - | |||
| NCT03552029 Details | 2022-05-20 Interventional | 1 | 10 | Quizartinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | This study was terminated based on a business decision by the Sponsor. This study was terminated based on a business decision by the Sponsor and was not due to a safety concern. | |||
| NCT03363503 Details | 2022-05-20 Interventional | 4 | 64 | Fluticasone Salmeterol Xina… Xhance Respiratory Asp… COPD | Adequate number of patients could not be reached in the relevant centers. - | |||
| NCT03332589 Details | 2022-05-20 Interventional | 1 | 4 | Dabrafenib Brain Neoplasms Melanoma Neoplasm Metast… Brain Metastase… Malignant Melan… | Single center study: Principal Investigator left institution. Due to the departure of the study PI from the institution, the study was terminated early. | |||
| NCT02953145 Details | 2022-05-20 Interventional | 4 | 0 | Fibrin Tissue A… Cleft Palate Pain, Postopera… | Lack of support - |